Clinical Trial Update: Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating Debio0123 in combination with sacituzumab govitecan for advanced breast cancer (TNBC or HR+/HER2-); study status is ACTIVE_N…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Debio0123
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: MedSIR | Conditions: Advanced Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING